2. Search Result
Search Result
Results for "

UGT1A1

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

4

Natural
Products

1

Isotope-Labeled Compounds

8

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160250
    UGT1A1-IN-1

    		UGT Metabolic Disease
    UGT1A1-IN-1 (compound 2) is a non-competitive inhibitor of UGT1A1, which can inhibit the 1-O-glucuronidation process mediated by UGT1A1 with a Ki value of 5.02 μM. UGT1A1-IN-1 (compound 2) can bind on UGT1A1 at the same ligand-binding site as bilirubin (HY-N0323). UGT1A1-IN-1 can serve as a ‘turn-on’ fluorescent probe substrate for UGT1A1 .
    UGT1A1-IN-1
  • HY-111832
    1,2,3,6-Tetragalloylglucose

    TeGG

    		 UGT Infection Metabolic Disease
    1,2,3,6-Tetragalloylglucose (TEgG) is a competitive inhibitor of UDP-glucuronyltransferase UGT1A1, targeting the competitive substrate binding site of UGT1A1. 1,2,3,6-Tetragalloylglucose inhibits UGT1A1-mediated β-estradiol 3-glucuronidation and SN-38 glucuronidation with IC50 of 6.01 μM and 4.31 μM, respectively, and binds to UGT1A1 with Ki of 3.55 μM. 1,2,3,6-Tetragalloylglucose also induces tumor cell apoptosis, inhibit cell proliferation, activates caspase-3 and induces DNA fragmentation in HL-60 cells. 1,2,3,6-Tetragalloylglucose also inhibits HIV integrase and reverse transcriptase, and inhibits HCV protease .
    1,2,3,6-Tetragalloylglucose
  • HY-108292
    Propacetamol hydrochloride

    		Others Cancer
    Propacetamol hydrochloride is an analgesic agent, can be used in induction of acute liver injury. Propacetamol hydrochloride acts function through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress. Propacetamol hydrochloride also is a precursor form of paracetamol. Propacetamol hydrochloride can be used in postoperative pain, acute trauma and gastrointestinal disorders .
    Propacetamol hydrochloride
  • HY-RS23238
    Ugt1a1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ugt1a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ugt1a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ugt1a1 Rat Pre-designed siRNA Set A
    Ugt1a1 Rat Pre-designed siRNA Set A
  • HY-RS15426
    UGT1A1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UGT1A1 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UGT1A1 Human Pre-designed siRNA Set A
    UGT1A1 Human Pre-designed siRNA Set A
  • HY-RS16797
    Ugt1a1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ugt1a1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ugt1a1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ugt1a1 Mouse Pre-designed siRNA Set A
    Ugt1a1 Mouse Pre-designed siRNA Set A
  • HY-RS15427
    UGT1A10 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UGT1A10 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UGT1A10 Human Pre-designed siRNA Set A
    UGT1A10 Human Pre-designed siRNA Set A
  • HY-100319
    UK-157147

    		UGT Metabolic Disease
    UK-157147 is a substrate for UDP-glucuronosyltransferases (UGT1A1) with a Km value of 105 μM.
    UK-157147
  • HY-124364
    RO6889678

    		HBV Cytochrome P450 Infection Metabolic Disease
    RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .
    RO6889678
  • HY-135581
    Raloxifene 6-glucuronide

    		Estrogen Receptor/ERR Endocrinology
    Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .
    Raloxifene 6-glucuronide
  • HY-170503
    MAT2A-IN-20

    		Methionine Adenosyltransferase (MAT) Cancer
    MAT2A-IN-20 (Compound A49) is an inhibitor for methionine adenosyltransferase 2A (MAT2A) with an IC50 ≤50 nM. MAT2A-IN-20 inhibits human UGT1A1 with an IC50 of 28.45 μM. MAT2A-IN-20 exhibits antitumor in mouse models .
    MAT2A-IN-20
  • HY-N0372
    Licochalcone A
    Maximum Cited Publications
    14 Publications Verification

    		 Autophagy Cancer
    Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .
    Licochalcone A
  • HY-N0372R
    Licochalcone A (Standard)

    		Reference Standards Autophagy Cancer
    Licochalcone A (Standard) is the analytical standard of Licochalcone A. This product is intended for research and analytical applications. Licochalcone A (LCA), a flavonoid isolated, presents obvious anti-cancer effects, displays broad-spectrum inhibition against UDP-glucuronosyltransferases (UGTs) . Licochalcone A (LCA) exhibits strong inhibitory effects against UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A9, and 2B7 (both IC50 and Ki values lower than 5 μM) .
    Licochalcone A (Standard)
  • HY-135581S1
    Raloxifene 6-glucuronide-d4 lithium

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Endocrinology
    Raloxifene 6-glucuronide-d4 (lithium) is deuterium labeled Raloxifene 6-glucuronide. Raloxifene 6-glucuronide is a primary metabolite of Raloxifene. Raloxifene 6-glucuronide is mediated mostly by UGT1A1 and UGT1A8. Raloxifene 6-glucuronide binds to estrogen receptor with an IC50 of 290 μM. Raloxifene is a selective and nonsteroidal estrogen receptor modulator. Raloxifene activates TGFβ3 promoter as a full agonist at nanomolar concentrations, and inhibits the estrogen response element-containing vitellogenin promoter expression .
    Raloxifene 6-glucuronide-d4 lithium
  • HY-N1902R
    4-Hydroxyphenylacetic acid (Standard)

    		Reference Standards Keap1-Nrf2 Endogenous Metabolite Metabolic Disease
    4-Hydroxyphenylacetic acid (Standard) is the analytical standard of 4-Hydroxyphenylacetic acid. This product is intended for research and analytical applications. 4-hydroxyphenylacetic acid, a major microbiota-derived metabolite of polyphenols, is involved in the antioxidative action. 4-hydroxyphenylacetic acid induces expression of Nrf2 . IC50 & Target:Nrf2 In Vivo: 4-Hydroxyphenylacetic acid (6, 12, or 25 mg/kg) increases Nrf2 translocation to the nucleus and enhances the activity of phase II and antioxidant enzymes. The protein levels of nuclear Nrf2 are increased by 170% and 230% in pre-treated 12 and 25 mg/kg 4-Hydroxyphenylacetic acid groups, respectively, compared with the control group.The 4-Hydroxyphenylacetic acid pretreatment at a final dose of 25 mg/kg markedly and selectively up-regulated the target genes of phase II enzymes and resulted in higher up-regulation than that of the control group by 270%, 400%, and 500% or UGT1A1, UGT1A9, and SULT2A1, respectively. 4-Hydroxyphenylacetic acid also suppresses the expression of CYP2E1 .
    4-Hydroxyphenylacetic acid (Standard)
  • HY-15592A
    Cabotegravir sodium
    5+ Cited Publications

    GSK-1265744 sodium; S/GSK1265744 sodium

    		 OAT HIV HIV Integrase Infection
    Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir sodium is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir sodium can be used to research AIDS .
    Cabotegravir sodium
  • HY-15592
    Cabotegravir
    5+ Cited Publications

    GSK-1265744; S/GSK1265744

    		 OAT HIV HIV Integrase Infection
    Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .
    Cabotegravir
  • HY-15592R
    Cabotegravir (Standard)

    GSK-1265744 (Standard); S/GSK1265744 (Standard)

    		 OAT Reference Standards HIV HIV Integrase Infection
    Cabotegravir (Standard) is the analytical standard of Cabotegravir. This product is intended for research and analytical applications. Cabotegravir (GSK-1265744) is a orally active and long-acting HIV integrase strand transfer inhibitor and organic anion transporter 1/3 (OAT1/OAT3) inhibitor with IC50 values of 2.5 nM, 0.41 μM and 0.81 μM for HIVADA, OAT3 and OAT1, respectively. Cabotegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1, with low potential to interact with other antiretroviral agents (ARVs). Cabotegravir can be used to research AIDS .
    Cabotegravir (Standard)
  • HY-111539
    BAY-1316957

    		Prostaglandin Receptor Inflammation/Immunology Endocrinology
    BAY-1316957 is a potent, selective and orally active prostaglandin E2 receptor subtype 4 (EP4-R) antagonist with an IC50 of 15.3 nM for human EP4-R. BAY-1316957 has excellent agent metabolism and pharmacokinetics properties, and can be used for endometriosis research .
    BAY-1316957
  • HY-RS15431
    UGT1A7 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UGT1A7 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UGT1A7 Human Pre-designed siRNA Set A
    UGT1A7 Human Pre-designed siRNA Set A
  • HY-RS15432
    UGT1A8 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UGT1A8 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UGT1A8 Human Pre-designed siRNA Set A
    UGT1A8 Human Pre-designed siRNA Set A
  • HY-RS15429
    UGT1A4 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UGT1A4 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UGT1A4 Human Pre-designed siRNA Set A
    UGT1A4 Human Pre-designed siRNA Set A
  • HY-RS15430
    UGT1A6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    UGT1A6 Human Pre-designed siRNA Set A contains three designed siRNAs for UGT1A6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    UGT1A6 Human Pre-designed siRNA Set A
    UGT1A6 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: